Dr. Nicholas Jackson joined CEPI in 2019, as the Head of Programs and Technology for R&D. CEPI’s mission is to accelerate the development of vaccines against emerging infectious diseases and enable access to these vaccines for people during outbreaks.
Recently prior to CEPI, Dr. Jackson was VP, Head of Research for Sanofi Pasteur, responsible to lead the two premier Research facilities in Cambridge MA and Lyon, France. Sanofi Pasteur is the largest company in the world devoted entirely to vaccines.
Dr. Jackson has spent over 20 years in the prophylactic & therapeutic vaccine industry in research and development, working on a variety of global vaccine programs (from early research through to Phase 3 & licensure) in disease areas including bacterial, viral and neurological targets. He has lived and worked in the UK, Belgium, the United States and France.
Dr. Jackson was trained in the United Kingdom and holds a Bachelor of Science degree from Oxford Brookes University, a master of science from the London School of Hygiene & Tropical Medicine, and a doctorate from the University of Warwick in the field of viral immunology. He has served on, and continues to provide expertise for, several advisory groups in the field of vaccines.